Acquisition Details
Genmab has completed its tender offer to acquire all outstanding common shares of Merus N.V. for $97 per share, achieving 94.2% ownership. The transaction supports Genmab's strategy to expand its revenue and diversify its portfolio.
Petosemtamab Integration
The acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's pipeline. Genmab plans to launch petosemtamab in 2027, pending clinical results and regulatory approvals, and expects it to significantly contribute to EBITDA by 2029.
Subsequent Offering Period
A subsequent offering period is open from December 12 to December 29, 2025, allowing remaining Merus shareholders to tender their shares at the same price. Genmab aims to acquire 100% of Merus through additional transactions following this period.
